Treatment Of Advanced NSCLC Research Articles

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

IntroductionThe standard chemotherapy for squamous NSCLC (sqNSCLC) includes platinum plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody, plus platinum and gemcitabine (GP) has revealed encouraging efficacy as first-line therapy for sqNSCLC in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to further compare the efficacy and safety of sintilimab with placebo, both in combination with GP. MethodsORIENT-12, a randomized, double-blind, phase 3 study, was conducted at 42 centers in the People’s Republic of China (ClinicalTrials.gov, number NCT03629925). Patients with locally advanced or metastatic sqNSCLC and without EGFR-sensitive mutations or ALK rearrangements were enrolled in the study. The stratification factors included clinical stage, choice of platinum, and programmed death-ligand 1 tumor proportion score. The patients, investigators, research staff, and sponsor team were masked to treatment assignment. Eligible patients were randomized 1:1, using an integrated web-response system, to receive sintilimab 200 mg or placebo plus GP every 3 weeks for four or six cycles, followed by sintilimab or placebo as maintenance therapy until disease progression or 2 years. The primary end point was progression-free survival (PFS), assessed by an independent radiographic review committee. ResultsBetween September 25, 2018 and July 26, 2019, a total of 543 patients were screened, of whom 357 patients were randomized to the sintilimab-GP group (n = 179) and the placebo-GP group (n = 178). After a median follow-up period of 12.9 months, sintilimab-GP continued to reveal a meaningful improvement in PFS than placebo-GP (hazard ratio = 0.536 [95% confidence interval: 0.422–0.681], p < 0.00001). Treatment-emergent adverse events of grade 3 or worse occurred in 86.6% patients in the sintilimab-GP group and in 83.1% in the placebo-GP group. The incidence of treatment-emergent adverse event leading to death was 4.5% and 6.7% in the two treatment groups, respectively. ConclusionsRegarding PFS, sintilimab plus GP reveals clinical benefit than GP alone as first-line therapy in patients with locally advanced or metastatic sqNSCLC. The toxicity was acceptable, and no new unexpected safety signals were observed.

Platinum-based chemotherapy combined with endostar in the treatment of advanced NSCLC: A real world study.

e21033 Background: Recombinant human endostatin (endostar), an angiogenesis inhibitor, has been approved for the treatment of NSCLC in combination with chemotherapy in China. This study aims to evaluate real world efficacy and safety of endostar combined with platinum-based chemotherapy in the treatment of advanced NSCLC. Methods: This study retrospectively collected electronic medical record system (EMR) information of NSCLC patients (pts) who received endostar combined with platinum-based chemotherapy regiments from June 2012 to August 2019 in 7 cancer hospitals after obtaining ethical approval. Baseline characteristics, efficacy evaluation and safety data were analyzed. Tumor response was evaluated according to RECIST 1.1. Adverse events (AEs) were graded according to NCI-CTC AE 4.0. The endpoints include objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and safety. Results: 512 advanced NSCLC pts who received endostar combined with platinum-based chemotherapy regiments were analyzed. The median age of pts was 59.2 years. Most pts were male, accounting for 75.2%. 63.3% pts was diagnosed at stage IV. 40.0% pts was adenocarcinoma and 35.4% pts was squamous cell carcinoma. 81.4% pts received endostar combined with chemotherapy as first-line. 292 people were included in the efficacy analysis set. The ORR, DCR and median PFS were 34%, 73% and 8.2 (95% CI 6.0-13.7) months, respectively. There were no significant differences of ORR and DCR among common platinum-based chemotherapy. The most common AEs were gastrointestinal reactions (29%), bone marrow suppression (14%), and liver damage (12%). Conclusions: The real-world data confirmed the superiority of endostar plus platinum-based chemotherapy in Chinese advanced NSCLC pts, with acceptable adverse effects. Clinical trial information: ChiCTR2000035129.

Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.

9002 Background: PD-L1/PD-1 inhibitors have transformed the treatment (tx) of advanced NSCLC. Evidence suggests that the occurrence of irAEs with these agents may predict improved outcomes in cancers such as NSCLC. Atezolizumab (atezo; anti–PD-L1) has shown efficacy and tolerability in NSCLC and is currently approved in the 1L and 2L+ settings. The Ph 3 IMpower130, IMpower132 and IMpower150 trials evaluated atezo + chemo ± bevacizumab (bev) as 1L tx of NSCLC. We explore the association between irAEs and efficacy in these trials. Methods: Each trial enrolled tx-naive patients (pts) with nonsquamous stage IV NSCLC. Pts were randomized to: carboplatin (carbo) + nab-paclitaxel alone or with atezo in IMpower130; carbo or cisplatin alone or with atezo in IMpower132; atezo (A) + bev (B) + carbo + paclitaxel (CP), ACP or BCP in IMpower150. Data were pooled (data cutoffs: Mar 15 2018 [IMpower130]; May 22 2018 [IMpower132]; Sep 13 2019 [IMpower150]) and analyzed by tx (atezo-containing vs control) and irAE status. A time-dependent Cox model and landmark analyses at 1, 3, 6 and 12 mo were used to control for immortal bias. Study protocols required atezo tx interruption/discontinuation for grade (Gr) ≥3 irAEs. Results: 2503 pts were included in the analysis (atezo, n = 1577; control, n = 926). In both arms, baseline characteristics were generally balanced between pts with irAEs (atezo, n = 753; control, n = 289) and without irAEs (atezo, n = 824; control, n = 637). Any-Gr irAEs occurred in 48% (atezo) and 32% (control) of pts; Gr 3-5 irAEs occurred in 11% (atezo) and 5% (control). The most common irAEs (atezo vs control) were rash (28% vs 18%), hepatitis (lab abnormalities; 15% vs 10%) and hypothyroidism (12% vs 4%). Median time to onset of first irAE was 1.7 (atezo) vs 1.4 mo (control). OS HRs (95% CI) from the time-dependent Cox model between pts with vs without irAEs were 0.69 (0.60, 0.78) in the atezo arm and 0.82 (0.68, 0.99) in the control arm; after excluding rash (perceived as the least specific irAE), OS HRs (95% CI) were 0.75 (0.65, 0.87) and 0.90 (0.71, 1.12), respectively. OS landmark data are in the Table. Conclusions: In this exploratory pooled analysis, pts with irAEs had longer OS vs pts without irAEs in the atezo-containing and control arms per the time-dependent Cox model and landmark analyses; this trend remained for the atezo arm after excluding rash. Landmark analyses suggest that in the atezo arm, pts with Gr 1/2 irAEs had the longest OS and pts with Gr ≥3 irAEs had the shortest OS, potentially due to tx interruption/discontinuation. Clinical trial information: NCT02367781; NCT02657434; NCT02366143. [Table: see text]

RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.

9102 Background: Tislelizumab is a humanized, monoclonal antibody with high affinity and specificity for the programmed cell death protein 1 (PD-1). It has demonstrated antitumor activity in advanced lung cancers. We conducted a Phase 3, multicenter, randomized open-label study (NCT03594747) to assess the safety and efficacy of tislelizumab plus chemotherapy in patients (pts) with advanced squamous NSCLC. As previously reported, tislelizumab (TIS) significantly improved progression free survival (PFS) and reduced the risk of progression. Here, we report results from a sub-group of pts aged ≥ 65 years. Methods: Eligible pts (aged 18-75 years) enrolled in China were treatment-naive for locally advanced or metastatic squamous NSCLC. Pts were stratified by disease stage (IIIB vs IV), and programmed death-ligand 1 (PD-L1) expression (&lt;1% vs 1-49% vs 50% tumor cells), and randomized 1:1:1 to Arm A: TIS 200 mg + paclitaxel (P) 175 mg/m2 and carboplatin (C) area under the plasma concentration 5 (every 3 weeks [Q3W] on day 1); Arm B: TIS + nab-paclitaxel ( nab-P) 100 mg/m2 (Q3W on days 1, 8 and 15) + C (Q3W on Day 1); or Arm C: P + C (Q3W on day 1). P, nab-P and C were administered for 4 to 6 cycles. TIS was administered until loss of benefit, withdrawal of consent or start of a new anticancer therapy. In this sub-group analysis, pts aged ≥ 65 years were evaluated according to the primary endpoint (PFS) and key secondary endpoints (objective response rate and safety). Results: Overall, 127 pts aged ≥ 65 years were randomized to receive treatment. Median age of pts aged ≥ 65 was 68.0 years and 120 pts (94.5%) were male. In total, 18 (46.2%), 20 (38.5%), and 34 (94.4%) pts in Arms A, B and C, respectively, had discontinued treatment. In Arm C 22/34 pts had completed chemotherapy. The primary and secondary endpoints, PFS and ORR, were longer and higher, respectively, in Arms A and B, compared with Arm C (Table). Grade ≥ 3 treatment related adverse events (TRAEs) occurred in 33 (84.6%), 44 (84.6%) and 28 (82.4%) pts aged ≥ 65 years in Arms A, B and C, respectively, compared with 103 (85.8%), 99 (83.9%) and 94 (80.3%) pts aged ≥ 18 years enrolled in the study. The most commonly reported TRAEs in pts aged ≥ 65 years were anemia, decrease in neutrophil count, and alopecia. Conclusions: In this sub-group analysis, PFS and ORR were longer and higher, respectively, with TIS in pts aged ≥ 65 years with advanced squamous NSCLC. The safety profile of TIS in pts aged ≥ 65 years was similar to the safety profile for all aged pts aged ≥ 18 years. Clinical trial information: NCT03594747. [Table: see text]

Outcomes and safety analysis of a phase IB trial of stereotactic body radiotherapy (SBRT) to all sites of oligometastatic non-small cell lung cancer combined with durvalumab and tremelimumab.

e21212 Background: Combining local ablative and systemic therapies in patients with oligometastatic NSCLC leads to improved overall survival (OS) and progression-free survival (PFS). The potential immunostimulatory effects of ablating all visible disease with SBRT in combination with dual immune checkpoint inhibition has prompted interest, but the toxicity and benefit are unknown. Methods: We conducted a phase Ib study to investigate the safety of SBRT, with doses between 30 and 50 Gy in five fractions to all sites of disease, followed by durvalumab 1500 mg IV in combination with tremelimumab 75 mg IV every 4 weeks x 4 cycles, followed by durvalumab maintenance until progression. Eligible patients had 1-6 extracranial metastatic sites, allowing multiple metastases per location, with all lesions suitable for SBRT, ECOG performance status 0-1, no actionable driver mutation, and no prior immunotherapy. The primary endpoint was safety of this combination. Secondary endpoints include PFS and OS. Dose-limiting toxicities (DLTs) (any Grade ≥ 3 toxicity) were evaluated from the first administration of SBRT until 28 days post start of durvalumab and tremelimumab. Baseline tumor mutational burden, PD-L1 expression on post-SBRT biopsy and circulating tumor cells will be correlated with outcomes. In this first cohort analysis, we assess the safety and outcomes of the first 17 patients. Results: From 2/2018-2/2021, the first 17 pts were enrolled. Characteristics of those enrolled included: median age 68 years, female/male 4/13, squamous/non-squamous 2/15, median number of non-central nervous system (CNS) metastatic sites 2 (1-5), median number of non-CNS metastatic lesions 2 (1-9), CNS involvement 6/17 (35.3%), previous treatment 4/17 (23.5%). DLTs were seen in 2/17 (11.8%) patients; DLTs were autoimmune hepatitis and autoimmune pancreatitis. Most treatment-related adverse events (TRAEs) were grade (G) 1/2. TRAEs included: all TRAEs n = 188, 88.2% (of patients); G 3 n = 17, 29.4%; G 4 n = 1, 5.8%. There were no treatment-related deaths. Five patients discontinued treatment due to grade 3/4 immune related adverse events (IRAE). At a median follow up of 20 months 11/17 (64.7%) patients are alive with 10/17 (58.8%) with no evidence of disease (NED). Six of 17 (35.2%) patients experienced disease progression and 4/17 (23.5%) patients died of disease progression. Median PFS and OS are not yet reached. Conclusions: There were no unexpected safety signals in the cohort of patients enrolled. The incidence of grade ≥ 3 IRAEs is similar to the treatment of advanced NSCLC and no additional toxicity was observed with the addition of SBRT. Clinical outcomes look promising with median OS and PFS not yet reached at 20 months median follow up. The study continues to enroll a second cohort and results will be updated. Clinical trial information: NCT03275597.

Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

9078 Background: Cemiplimab, a PD-1 inhibitor, improved survival and progression-free survival vs platinum doublet chemotherapy (chemo) in patients (pts) with advanced NSCLC and PD-ligand(L)1 expression ≥50% in the EMPOWER-Lung 1 Phase 3 study (NCT03088540). Since pts with advanced NSCLC have a high symptom burden that adversely impacts QoL and functioning, these outcomes were evaluated as secondary endpoints in the clinical trial. Methods: Pts with advanced NSCLC with PD-L1 expression ≥50% and ECOG performance status ≤1 were randomized to IV cemiplimab 350 mg Q3W (n=356) or platinum doublet chemo (n=354). At baseline (BL) and day 1 of each treatment cycle (C) to C15, pts were administered the EORTC core questionnaire (QLQ-C30) and its lung cancer specific module (QLQ-LC13) to assess symptoms, functioning, and Global Health Status (GHS)/QoL. In the intent-to-treat population, mixed-effects repeated measures models were used to estimate least squares (LS) mean change from BL on all scales. Kaplan–Meier analysis estimated time to definitive deterioration, defined as worsening ≥10 points from BL observed at all subsequent time points or patient withdrawal after worsening; hazard ratios (HR) with 95% CIs estimated the likelihood of definitive deterioration. Results: BL scores showed moderate to high levels of functioning and low symptom burden. Cemiplimab-treated pts had lower likelihood of definitive deterioration vs chemo on key symptoms of dyspnea, cough, pain in chest, pain in other body parts, fatigue, nausea/vomiting, appetite loss, constipation, and diarrhea vs chemo (all P&lt;.05). Treatment-related symptoms of peripheral neuropathy and alopecia had a lower likelihood of definitive deterioration with cemiplimab vs chemo (both P&lt;.05). Cemiplimab resulted in significantly greater improvements vs chemo on all functioning scales and reduced the likelihood of definitive deterioration as indicated by HR &lt;1 (Table). GHS/QoL improvements with cemiplimab at C2 were maintained to C15; LS mean change (SE) from BL across all timepoints was 7.1 (1.0) for cemiplimab vs 1.7 (1.2) for chemo ( P&lt;.0001). Conclusions: In pts with advanced NSCLC and PD-L1 expression ≥50%, cemiplimab significantly improved GHS/QoL, functioning, and most symptoms vs chemo. Over 1 year of treatment, cemiplimab delayed worsening of key lung cancer symptoms and functioning. Clinical trial information: NCT03088540. [Table: see text]

PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy.

Treatment strategies for advanced NSCLC patients without driver molecular alterations are influenced by PD-L1 expression. If PD-L1 is <50 %, the preferred upfront treatment is the association of chemotherapy and immunotherapy, while immunotherapy alone is an additional option if PD-L1 ≥ 50 %. Both treatments demonstrated their superiority over chemotherapy in this subset of NSCLC patients, with comparable efficacy outcomes but less safety concerns for immunotherapy alone. Nevertheless, a significant difference in terms of early progression-free survival rate emerges by analyzing and comparing the survival curves of the two strategies, reflecting a non-negligible loss of patients due to early disease progression at 3 and 6 months from treatment initiation with immunotherapy alone as compared to its association with chemotherapy. We deeply analyzed efficacy similarities and differences of the two approaches in advanced NSCLC with PD-L1 expression ≥50 %, trying to suggest clinical and biologic aspects to be considered when facing the treatment choice.

The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations.

At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, and described the different testing modalities for molecular markers.

96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

116P Real-world outcomes of patients with metastatic non-small cell lung cancer receiving 2L+ atezolizumab-based treatments in Taiwan clinical practice

Background: In the pivotal OAK study, the 2/3L treatment for advanced or metastatic NSCLC with atezolizumab (atezo) resulted in improvement of OS. Despite its efficacy has been approved, little is known about atezo clinical outcomes in routine practice in the Asian population. This study aimed to understand the clinical characteristics and outcomes of NSCLC patients treated with atezo in second-line and beyond (2L+) in the real-world setting.

151P Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for advanced NSCLC with EGFR-positive mutation patients: A systematic review

151P Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for advanced NSCLC with EGFR-positive mutation patients: A systematic review

Nivolumab in the first-line treatment of advanced NSCLC

Nivolumab in the first-line treatment of advanced NSCLC

P86.09 A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC

Patients with driver mutation-negative advanced NSCLC are mostly treated with platinum-based systemic therapy as the standard first-line therapy, but which achieves no satisfactory efficacy outcomes. Previous clinical studies exhibit that bevacizumab, an anti-VEGF inhibitor, plus chemotherapy improves survival for first-line treatment of advanced non-squamous NSCLC. Anlotinib, a novel oral multitarget tyrosine kinase inhibitor primarily targeting VEGFR2/3, FGFR1-4, PDGFRα/β and c-Kit, effectively inhibits angiogenesis and enhances tumor cell response to chemotherapy. The phase III ALTER 0303 trial showed anlotinib significantly improved progression-free survival (PFS) and overall survival (OS) in third-line or further treatment of advanced NSCLC. This open-label, single-arm, multicenter phase II study aims to explore whether anlotinib, as an oral multi-targeted antiangiogenic drug, in combination with pemetrexed plus cisplatin could further improve outcomes as first-line therapy for patients with non-driver mutation advanced non-squamous NSCLC. The single-arm, multicenter phase II study is ongoing and evaluating the efficacy and safety of anlotinib plus pemetrexed plus cisplatin for first-line treatment of driver mutation-negative advanced non-squamous NSCLC (NCT03671538). Patients aged 18 to 75 years and with histologically or cytologically confirmed locally advanced or metastatic stage IIIB/IV non-squamous NSCLC not harboring EGFR、ALK、ROS1 or BRAF genomic alterations are eligible in this study. Patients have to have an Eastern Cooperative Oncology Group performance status of 0 or 1, and have received no previous systemic chemotherapy. Enrolled patients receive anlotinib (12 mg, QD, day 1 to 14 of a 21-day cycle) combined with pemetrexed (500 mg/m2, IV, day 1, 21 days per cycle) plus cisplatin (75 mg/m2, IV, day 1, 21 days per cycle). Those patients who have response or stable disease (SD) after 4-6 cycles of anlotinib in combination with pemetrexed plus cisplatin move to maintenance treatment with anlotinib alone (12 mg, QD, day 1 to 14 of a 21-day cycle) until disease progression or treatment intolerance. The primary endpoint is progression-free survival (PFS) according to RECIST v1.1. Secondary endpoints are 6-month and 12-month PFS rates, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. Based on previous research results, we assume that the median PFS in patients with driver mutation-negative advanced non-squamous NSCLC treated by anlotinib plus pemetrexed plus cisplatin as first-line therapy is 7.5 months, then take an alpha value of 0.2 and a beta valve of 0.8. The follow-up time is 12 months. Finally, this study plans to enroll 62 patients calculated by NCSS & PASS 15.0 software and a one-sample Logrank test. Currently, 18 patients have been enrolled in the study (until June 26, 2020). Clinical trial in progress. Clinical trial in progress. Anlotinib, first-line therapy, driver mutation-negative

P15.09 A Promising Result of Two Therapeutic Peptides Combined with Chemotherapy in the Treatment of Advanced NSCLC

P15.09 A Promising Result of Two Therapeutic Peptides Combined with Chemotherapy in the Treatment of Advanced NSCLC

P09.01 Different Administration Routes of Endostar Combined with Chemotherapy in the Treatment of Advanced NSCLC, a Real World Study

P09.01 Different Administration Routes of Endostar Combined with Chemotherapy in the Treatment of Advanced NSCLC, a Real World Study

P14.17 Low BMI is Associated with Inferior Overall Survival in HIV Patients with Advanced NSCLC Undergoing Immunotherapy

Increased body mass index (BMI) has been associated with poor outcomes in solid malignancies. However, a recent study showed that higher BMI was associated with improved overall survival (OS) in advanced non-small lung cancer (NSCLC) treated with atezolizumab. Whether the obesity paradox applies to HIV patients with advanced NSCLC is unknown, as HIV patients were generally excluded from previous immunotherapy trials. We conducted a retrospective study on HIV patients with advanced NSCLC undergoing treatment with immunotherapy from 9/1/2016 to 3/01/2020 at a NCI-designated cancer center in Bronx, New York. Information was collected including age, race, ethnicity, BMI, PD-L1 tumor proportion score (TPS), neutrophil-to-lymphocyte ratio (NLR), HIV viral load (VL), and CD4/CD8 count at therapy initiation. Patients were categorized into underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), and overweight/obese BMI (≥ 25 kg/m2) per World Health Organization (WHO) categories. Data was collected until date of death, date of last contact, or censored after 3/1/20. The primary outcome was OS, and the secondary outcome for BMI was progression free survival (PFS). Cox proportional hazards was used to examine the association of BMI, NLR, and PD-L1 TPS with survival. Sixteen patients were identified who had HIV and received immunotherapy for treatment of advanced NSCLC. The mean age was 61.3 years. At treatment initiation, 9 had undetectable VL and 4 had detectable but unquantifiable VL, the mean CD4 count was 469, and the mean CD4/CD8 ratio was 0.69. Five patients were underweight, 4 were overweight/obese, and 7 patients had a normal BMI. Compared to patients with normal BMI, underweight patients had significantly worse OS (HR 12.3, 95% CI 2.02-74.5, p=0.006), and overweight/obese patients had similar OS (HR 0.93, 95% CI 0.17-5.22, p>0.9). PFS was not significantly different for underweight (HR 1.51, 95% CI 0.33, 6.86, 0.6) or overweight/obese (HR 1.88, 95% CI 0.41-8.63, p=0.4) patients. Patients with NLR ≥5 had a trend towards inferior OS (HR 3.39, 95% CI 0.96-12, p=0.057). PD-L1 TPS was available in 15 patients and was not a significant factor in OS at the >50% cutoff (HR 0.83, 95% 0.21-3.35, p=0.8). In our cohort of HIV patients with advanced NSCLC undergoing immunotherapy, compared to patients with normal BMI, underweight patients were observed to have significantly inferior OS. We acknowledge that the major shortcoming of current study is the small sample size, but even with this limited sample size, this finding was significant with a p-value of 0.006. Conversely, it is also possible that factors with borderline p-values, such as NLR, could also be significant in larger cohorts, and further investigation should continue.

P14.10 Efficacy of Anti-PD-1/PD-L1 Monoclonal Antibody Treatment of Advanced NSCLC on Density and Distribution of Tumor Infiltrating T Cells

P14.10 Efficacy of Anti-PD-1/PD-L1 Monoclonal Antibody Treatment of Advanced NSCLC on Density and Distribution of Tumor Infiltrating T Cells

A Giant Lung Tumor Disappeared After Crizotinib Treatment in an Elder Heavy Smoker: a Case Report

Updated data referring to efficacy and safety of crizotinib therapy have been presented. We reported a rare case of the 71-year-old elder heavy smoker with ALK-rearranged advanced lung adenocarcinoma. Within 7 months of crizotinib treatment, the giant lung tumor disappeared, and a complete response was achieved. The case illustrates exemplarily that crizotinib is effective and manageable as a first-line treatment in advanced NSCLC with ALK rearrangement. It also implies that the elder heavy smoker with such rare “god-given” ALK rearrangement might benefit more from ALK inhibitor.

Nivolumab in the First-Line Treatment of Advanced NSCLC

Nivolumab in the First-Line Treatment of Advanced NSCLC

67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1

67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1